Labcorp — Feb 6, 2025 release

• Expanded our Labcorp OnDemand test menu with new offerings to help consumers manage their health and well-being. • Introduced enhancements to Global Trial Connect aimed at increasing the speed of clinical trials. On January 8, 2025, Labcorp announced a quarterly cash dividend of $0.72 per share of common stock, payable on March 12, 2025, to stockholders of record at the close of business on February 27, 2025. 2 LABCORP HOLDINGS INC. CONSOLIDATED RESULTS Three Months Ended Dec 31, Year Ended Dec 31, 2024 2023 Delta 2024 2023 Delta Revenue Summary (Dollars in billions) Total Revenue $ 3.33  $ 3.03  9.8  % $ 13.01  $ 12.16  7.0  % Organic 5.4  % 3.9  % Base Business (1) 6.2  % 4.9  % COVID-19 Testing (2) (0.8  %) (1.0  %) Acquisitions, net of Divestitures 4.0  % 2.8  % Foreign Exchange 0.3  % 0.2  % (1) Base Business includes Labcorp’s operations except for COVID-19 Testing. (2) COVID-19 Testing represents COVID-19 PCR Testing. Earnings Summary (Dollars in millions, except per share data) Operating Income (“OI”) $ 216.5  $ (122.8) $ 1,086.7  $ 725.6  OI as % of Revenue 6.5  % (4.0) % 1,050 bps 8.4  % 6.0  % 240 bps Adjustments (3) $ 206.7  $ 517.7  $ 710.3  $ 989.3  Adjusted Operating Income (“AOI”) (4) $ 423.2  (5) $ 394.9  $ 1,797.0  $ 1,714.9  AOI as % of Revenue 12.7  % 13.0  % (40) bps (6) 13.8  % 14.1  % (30) bps (6) Net Earnings from Cont. Ops $ 143.6  $ (166.8) $ 747.1  $ 380.4  Diluted EPS from Cont. Ops $ 1.70  $ (1.95) $ 8.84  $ 4.33  Adjusted EPS (4) $ 3.45  $ 3.30  $ 14.57  $